Sarepta's FDA Push for PMO Full Approvals Faces Uphill Battle After Confirmatory Trial Miss

What happened

Sarepta Therapeutics plans to file for full FDA approval of its DMD therapies Amondys 45 and Vyondys 53, aiming to convert their accelerated approvals despite a missed endpoint in the ESSENCE confirmatory study. The DeepValue report highlights that ESSENCE failed to meet statistical significance (P=0.309), raising substantial regulatory risk under FDORA, which expedites withdrawal of accelerated approvals. This filing strategy leverages new data, but the company's own disclosures warn of potential FDA actions including label changes, revocation, or market removal, indicating no margin of safety. The move comes amid broader FDA scrutiny, with ELEVIDYS already facing a boxed warning and narrowed label, compounding operational and financial pressures. Investors should view this as a defensive maneuver to preserve the PMO revenue base, but success hinges on FDA leniency and data acceptance, which remains highly uncertain.

Implication

If the FDA accepts the new data, it could delay or prevent withdrawal actions, providing temporary relief for the ~$1 billion PMO revenue stream. However, the ESSENCE miss and FDORA framework make approval unlikely without compelling evidence, potentially leading to accelerated withdrawal steps. Failure could trigger a revenue decline of 25% or more, as per the bear case, exacerbating cash flow issues given fixed obligations like Arrowhead payments. This news does not address the ELEVIDYS overhang, where Q1'26 catch-up and infusion KPIs are critical for near-term valuation. Overall, while proactive, the filing adds another binary regulatory event, increasing near-term volatility without improving the fundamental risk-reward profile.

Thesis delta

The investment thesis remains unchanged; this news reinforces the WAIT rating by highlighting management's efforts to address PMO risks, but does not alter the high probability of FDA action or the need for observable ELEVIDYS recovery. Investors should continue to monitor Q1'26 results and FDA interactions as key catalysts, as outlined in the report's base and bear scenarios.